Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel

Author： Faulkner Michele A   Burke Rachel A  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.12, Iss.6, 2013-11, pp. : 847-855

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Retigabine (Ezogabine): In Partial-Onset Seizures in Adults with Epilepsy

By Deeks Emma D.  

CNS Drugs, Vol. 25, Iss. 10, 2011-10 ,pp. : 887-900

Adis International

Access to resources Recommend Favorite

Retigabine in partial seizures: profile report

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 22, Iss. 12, 2006-12 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

The Interaction Potential of Retigabine (Ezogabine) with Other Antiepileptic Drugs

By  

Current Clinical Pharmacology, Vol. 9, Iss. 2, 2014-05 ,pp. : 148-156

Bentham Science Publishers

Access to resources Recommend Favorite

Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures

By Rektor Ivan  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 2, 2013-02 ,pp. : 225-235

Informa Healthcare

Access to resources Recommend Favorite

Retigabine: In Partial Seizures

By Plosker Greg L.   Scott Lesley J.  

CNS Drugs, Vol. 20, Iss. 7, 2006-01 ,pp. : 601-608

Adis International

Access to resources Recommend Favorite